These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 20800345)

  • 1. Prevalence of non-motor dysfunction among Parkinson's disease patients from a tertiary referral center in Mexico City.
    Rodríguez-Violante M; Cervantes-Arriaga A; Villar-Velarde A; Corona T
    Clin Neurol Neurosurg; 2010 Dec; 112(10):883-5. PubMed ID: 20800345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Othello syndrome in patients with Parkinson's disease.
    Georgiev D; Danieli A; Ocepek L; Novak D; Zupancic-Kriznar N; Trost M; Pirtosek Z
    Psychiatr Danub; 2010 Mar; 22(1):94-8. PubMed ID: 20305599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of dopaminergic treatment on bladder function in Parkinson's disease.
    Winge K; Werdelin LM; Nielsen KK; Stimpel H
    Neurourol Urodyn; 2004; 23(7):689-96. PubMed ID: 15382192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of salivary secretion in Parkinson's disease.
    Bagheri H; Damase-Michel C; Lapeyre-Mestre M; Cismondo S; O'Connell D; Senard JM; Rascol O; Montastruc JL
    Clin Neuropharmacol; 1999; 22(4):213-5. PubMed ID: 10442250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine agonists in Parkinson's disease.
    Yamamoto M; Schapira AH
    Expert Rev Neurother; 2008 Apr; 8(4):671-7. PubMed ID: 18416667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of sudden onset of sleep in Parkinson's disease.
    Körner Y; Meindorfner C; Möller JC; Stiasny-Kolster K; Haja D; Cassel W; Oertel WH; Krüger HP
    Mov Disord; 2004 Nov; 19(11):1298-305. PubMed ID: 15389999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].
    Buchwald B; Angersbach D; Jost WH
    Fortschr Neurol Psychiatr; 2007 Apr; 75(4):236-41. PubMed ID: 17427044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson's disease.
    Barboi AC; Goetz CG
    Clin Neuropharmacol; 1999; 22(4):184-91. PubMed ID: 10442246
    [No Abstract]   [Full Text] [Related]  

  • 10. [Motor fluctuations and dyskinesias in Parkinson's disease: variables that discriminate both complications in a sample of 285 patients].
    Gómez JC; Rouco I; Velasco F; Tijero B; Garamendi I; Lezcano E; Zarranz JJ
    Neurologia; 2008 Oct; 23(8):494-8. PubMed ID: 18770057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence and correlates of neuropsychiatric symptoms in a population with Parkinson's disease in Mexico.
    Ringman JM; Diaz-Olavarrieta C; Rodriguez Y; Fairbanks L; Cummings JL
    Neuropsychiatry Neuropsychol Behav Neurol; 2002 Jun; 15(2):99-105. PubMed ID: 12050472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
    J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The use of antiparkinsonism drugs in 92 cases in Xi'an city].
    Zhe X; Qu QM; Wang RL; Cao HM; Qiao J; Guo F
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Oct; 30(10):1065-8. PubMed ID: 20193391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Punding prevalence in Parkinson's disease.
    Miyasaki JM; Al Hassan K; Lang AE; Voon V
    Mov Disord; 2007 Jun; 22(8):1179-81. PubMed ID: 17230464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restless legs syndrome in Parkinson's disease.
    Peralta CM; Frauscher B; Seppi K; Wolf E; Wenning GK; Högl B; Poewe W
    Mov Disord; 2009 Oct; 24(14):2076-80. PubMed ID: 19691124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson's goal: ease symptoms, slow progression.
    Johns Hopkins Med Lett Health After 50; 2006 Jun; 18(4):4-5. PubMed ID: 16795901
    [No Abstract]   [Full Text] [Related]  

  • 17. Prevalence of Parkinson's disease in Northern Jordan.
    Alrefai A; Habahbih M; Alkhawajah M; Darwish M; Batayha W; Khader Y; El-Salem K
    Clin Neurol Neurosurg; 2009 Dec; 111(10):812-5. PubMed ID: 19733962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
    Benbir G; Ozekmekçi S; Apaydin H; Delil S; Erginöz E
    Clin Neurol Neurosurg; 2006 Dec; 108(8):726-32. PubMed ID: 16564615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impulse control disorders in Parkinson disease: a multicenter case--control study.
    Voon V; Sohr M; Lang AE; Potenza MN; Siderowf AD; Whetteckey J; Weintraub D; Wunderlich GR; Stacy M
    Ann Neurol; 2011 Jun; 69(6):986-96. PubMed ID: 21416496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.
    Rascol O; Brooks DJ; Brunt ER; Korczyn AD; Poewe WH; Stocchi F
    Mov Disord; 1998 Jan; 13(1):39-45. PubMed ID: 9452324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.